issue of Hypertension. They showed that leptin suppresses cardiac contractile function in ventricular myocytes by an endothelin-1 and NADPH oxidase-dependent pathway.
Response: Leptin, Endothelin, NADPH Oxidase, and Heart Failure
We thank Morawietz and Bornstein for their thoughtful comments of our study. They raised an important point regarding the role of endothelin (ET)-1 and NADPH oxidase in cardiac dysfunction under hyperleptinemia. Given the fact that leptin suppresses cardiac contractile function and contributes to cardiac hypertrophy, the previously identified leptin signaling molecules including NO, Janus kinase/signal transducers and activators of transcription, and p38 mitogen-activated protein kinase cannot satisfactorily explain the pathophysiological consequence of hyperleptinemia. 1 Involvement of ET-1 in leptin-induced cardiomyocyte dysfunction adds a new sniper assignment to this "classical" cardiovascular culprit factor under hyperleptinemia. Our observation of ET-1 receptor-mediated NADPH oxidase activation and reactive oxygen species accumulation after leptin exposure is consistent with the finding of Duerrschmidt et al 2 of ET-1-induced NADPH oxidase expression and superoxide formation in human endothelial cells (HUVECs). Morawietz and Bornstein also raised an issue that additional NADPH oxidase complexes may be involved in the onset and progression of cardiovascular diseases, because only p22 phox , p47 phox , p67 phox , and gp91 phox were evaluated in our study. We fully agree with this point that leptin-induced cardiomyocyte contractile response may involve novel NADPH oxidase.
Leptin is closely associated with ET-1. ET-1 stimulates leptin production in adipocytes. Vice versa, leptin may facilitate ET-1 production in endothelial cells and cardiomyocytes. Such a link between leptin and ET-1 may explain a myocardial defect under hyperleptinemia. ET-1 plays an important role in cardiac contractile function mainly mediated by ET A receptors with the ET B receptor playing a minor role. Myocardial expressions of ET A and ET B receptors are both elevated in heart failure and myocardial infarction. However, in a transgenic mice model with elevated myocardial ET-1 levels, prolongation of survival was only achieved when both ET A /ET B receptors, rather than just ET A receptor, are blocked, indicating an important role for ET B . 3 Duerrschmidt et al 2 found that ET-1 induces superoxide formation and gp91 phox mRNA expression via an ET B -mediated pathway in HUVECs, supporting the significance of the ET B receptor. Consistently, our earlier observation indicated that ET-1 enhanced reactive oxygen species generation, which was prevented by the ET B receptor antagonist BQ788 or the NADPH oxidase inhibitor apocynin in HUVECs. 4 Nonetheless, little information is available regarding the involvement of any novel NADPH oxidase after ET B receptor activation.
Although elevated plasma leptin levels are deemed as an independent risk factor for the development of cardiovascular e20 Letter to the Editor disease, such as myocardial infarction, cardiac contractile dysfunction exists in both hyperleptinemic (db/db) and hypoleptinemic (ob/ob) mice. The cardiac defect (contractile dysfunction and poor ␤-adrenergic responsiveness) in ob/ob mice can be reversed with leptin replenishment, 5, 6 indicating a double-edged sword for leptin on heart function. Based on these findings, we believe that physiological levels of leptin may be beneficial for cardiac function, whereas pathological leptin levels (too much or too little) may be detrimental to cardiac function. A better understanding of the role of ET-1 and its downstream signaling mechanisms in leptinor hyperleptinemia-induced regulation of cardiac contractile function should provide insights for the therapeutic remedy of obesityassociated cardiovascular complications.
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